- Home
- OTLK vs ECOR Comparison
OTLK vs ECOR Comparison
Compare OTLK & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- ECOR
- Stock Information
- Founded
- OTLK 2010
- ECOR 2005
- Country
- OTLK United States
- ECOR United States
- Employees
- OTLK N/A
- ECOR N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- OTLK Health Care
- ECOR Health Care
- Exchange
- OTLK Nasdaq
- ECOR Nasdaq
- Market Cap
- OTLK 42.8M
- ECOR 37.1M
- IPO Year
- OTLK 2016
- ECOR 2018
- Fundamental
- Price
- OTLK $1.15
- ECOR $5.00
- Analyst Decision
- OTLK Buy
- ECOR Strong Buy
- Analyst Count
- OTLK 5
- ECOR 2
- Target Price
- OTLK $5.25
- ECOR $25.50
- AVG Volume (30 Days)
- OTLK 2.7M
- ECOR 45.7K
- Earning Date
- OTLK 08-14-2025
- ECOR 11-12-2025
- Dividend Yield
- OTLK N/A
- ECOR N/A
- EPS Growth
- OTLK N/A
- ECOR N/A
- EPS
- OTLK N/A
- ECOR N/A
- Revenue
- OTLK $1,505,322.00
- ECOR $27,700,000.00
- Revenue This Year
- OTLK N/A
- ECOR $24.48
- Revenue Next Year
- OTLK $343.94
- ECOR $44.35
- P/E Ratio
- OTLK N/A
- ECOR N/A
- Revenue Growth
- OTLK N/A
- ECOR 30.16
- 52 Week Low
- OTLK $0.79
- ECOR $4.16
- 52 Week High
- OTLK $6.98
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- OTLK 46.22
- ECOR 46.15
- Support Level
- OTLK $1.04
- ECOR $4.86
- Resistance Level
- OTLK $1.13
- ECOR $5.28
- Average True Range (ATR)
- OTLK 0.07
- ECOR 0.27
- MACD
- OTLK 0.05
- ECOR 0.04
- Stochastic Oscillator
- OTLK 84.91
- ECOR 43.40
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.